PSMA PET/CT Scan for Prostate Cancer: A Patient's Guide

A PSMA PET/CT scan is one of the most powerful tools now available for locating prostate cancer in the body. If your doctor has ordered one — or mentioned it as a next step — this guide explains exactly what the scan is, why it's used, what to expect, and how to understand your results.

Key Takeaways

PSMA stands for Prostate-Specific Membrane Antigen, a protein found in up to 1,000 times higher amounts on prostate cancer cells than on normal cells.
The scan combines a PET tracer that targets cancer cells with a standard CT scan, pinpointing disease with higher accuracy than conventional imaging.
It is most commonly ordered for high-risk prostate cancer staging or to find the source of a rising PSA after surgery or radiation.
The American College of Radiology finalized a new Practice Parameter for PSMA PET/CT in 2026, standardizing how the scan is performed and reported.
Most patients tolerate the procedure well; the total visit takes roughly 2–3 hours.

What Is a PSMA PET/CT Scan?

PSMA PET/CT is a type of nuclear medicine imaging that combines two technologies: a Positron Emission Tomography (PET) scan and a Computed Tomography (CT) scan performed together in the same session.

The key ingredient is the radiotracer — a slightly radioactive compound that is injected into your vein. This tracer is designed to bind tightly to PSMA, a protein that prostate cancer cells display in very high quantities. Once the tracer attaches to cancer cells, those cells light up on the PET scan, showing your care team exactly where disease may be present throughout your body — in lymph nodes, bones, or other organs.

The FDA has approved two PSMA-targeted tracers for clinical use: piflufolastat F-18 (brand name Pylarify, approved May 2021) and Ga 68 PSMA-11 (brand name Illuccix, approved December 2022). Both are available at major cancer centers and academic medical centers across the United States.

How Is This Different From a Prostate MRI?

A prostate MRI (reported with PI-RADS scores) looks inside the prostate gland itself to detect or characterize a tumor. A PSMA PET/CT scan looks at the whole body to find cancer that has spread — or may be starting to spread — beyond the prostate. The two tests answer different questions and are often used at different stages of care. If you've already had a prostate MRI and PI-RADS results, a PSMA PET/CT may be the logical next step if your doctor suspects spread.

When Doctors Order a PSMA PET/CT

Doctors order PSMA PET/CT in two main clinical situations:

1. Initial staging of high-risk or very-high-risk prostate cancer. When a biopsy confirms aggressive prostate cancer (Gleason score 8–10 or PSA over 20 ng/mL), the PSMA PET/CT helps determine whether the cancer is still contained in the prostate or has spread to nearby lymph nodes or distant sites. This directly shapes treatment planning — whether you need surgery alone, radiation, or systemic therapy as well.

2. Biochemical recurrence — rising PSA after treatment. This is the most common reason the scan is ordered. When PSA levels start rising again after a radical prostatectomy or radiation therapy, it signals that some cancer cells are still active. Conventional CT and bone scans often cannot detect disease at very low PSA levels (below 1–2 ng/mL). Studies published in the Journal of Clinical Oncology have shown PSMA PET/CT detects recurrent prostate cancer in up to 95% of cases, compared with roughly 30–58% for conventional imaging — a major difference at the critical window when early salvage treatment can still work.

According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), PSMA PET/CT is now considered the preferred staging test for high-risk prostate cancer at major cancer centers.

What to Expect: Step by Step

Before Your Appointment

Your imaging center will give you specific preparation instructions. Most centers require no special diet.
Tell your team about all medications you take. Some hormone therapies may temporarily reduce PSMA expression, so your doctor may time the scan around your treatment schedule.
Drink water and urinate frequently before the scan; the tracer is cleared through the kidneys, and a full bladder can obscure nearby structures.

At the Imaging Center

Tracer injection (5 minutes): A technologist places an IV and injects the PSMA-targeted radiotracer. You will not feel any significant effect from the injection.
Uptake period (60–120 minutes): You wait in a quiet area while the tracer circulates and binds to cancer cells. Most centers allow you to bring reading material or listen to music.
PET/CT scan (20–40 minutes): You lie still on a table that passes through the scanning ring. The combined PET and CT images are acquired in a single pass. The table moves slowly; the machines are open on both ends.
You're done. You can drive yourself home, eat and drink normally, and resume all activities immediately.

The total radiation dose from a PSMA PET/CT is typically 3–7 millisieverts (mSv) — roughly equivalent to 1–3 years of natural background radiation, and similar to a standard CT scan of the chest and abdomen.

Understanding Your PSMA PET/CT Report

Your radiologist or nuclear medicine physician will describe any areas where the radiotracer concentrated abnormally. Key terms to know:

PSMA-avid lesion: An area where the tracer accumulated — suggesting prostate cancer is present. "Avid" means the tissue is actively taking up the radiotracer.
SUV (Standardized Uptake Value): A number measuring how intensely the tracer concentrated in a spot. Higher SUV generally indicates more active disease, though your doctor interprets this in full clinical context.
Miraluma score / PSMA expression score: Some reports use a standardized scoring system (similar to PI-RADS or BI-RADS) to categorize likelihood that a finding represents cancer.
No PSMA-avid disease identified: A reassuring result meaning no areas of abnormal tracer uptake were detected.

A negative PSMA PET/CT does not 100% rule out cancer — very small deposits can fall below the scan's detection threshold (~5 mm). Your oncologist will always interpret the result together with your PSA trend and clinical history.

For a broader explanation of how PET scan reports are structured, see our guide to reading a PET scan report.

Frequently Asked Questions

Is a PSMA PET/CT the same as a regular PET scan?

No. A standard PET scan uses a glucose-based tracer (FDG) that highlights any fast-dividing cells. PSMA PET/CT uses a prostate-cancer-specific tracer that binds only to cells expressing PSMA — making it far more accurate for prostate cancer. FDG PET is generally used for other cancers such as lymphoma and lung cancer.

Will the radiotracer affect my PSA level?

No. The PSMA tracer does not interact with PSA or affect your hormone levels. You can have your PSA drawn before or after the scan without concern.

How soon will I get my results?

Most centers provide a preliminary report within 24–48 hours. Your oncologist will then schedule a follow-up visit to review what the scan found and discuss next steps.

Does insurance cover PSMA PET/CT?

Medicare and most major commercial insurers now cover PSMA PET/CT for both initial high-risk staging and biochemical recurrence. Coverage rules vary, so confirm with your insurance before the appointment. Your imaging center's pre-authorization team can assist.

Is the scan safe if I have a pacemaker or metal implants?

Yes — PET/CT does not use magnets (unlike MRI), so pacemakers and most metal implants are not a concern. Inform your care team about any implants so they can note them for the report.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment decisions.